Federal Circuit Upholds Allergan Win Over Lumigan Patent

The Federal Circuit ruled in favor of specialty pharmaceutical company Allergan, affirming a district court’s ruling that two generic-drug makers would infringe on Allergan’s patent if they continued plans to manufacture a generic version of glaucoma drug Lumigan (bimatoprost).
Law360